InstalabLoading...
InstalabLoading...
Most people think of bile only as a fat-digesting fluid. But the specific bile acids your liver makes, and what your gut bacteria do with them, send signals that ripple through your blood sugar control, your inflammation levels, your bone metabolism, and even your heart. HCA (hyocholic acid) is one of those signals. People with obesity, prediabetes, and type 2 diabetes consistently show lower levels of HCA species, and lower baseline levels predict who is more likely to develop metabolic disease over the next 5 to 10 years.
HCA is a research marker, not a diagnostic test. There are no standardized clinical cutoffs, and a single number on its own does not diagnose anything. What it can do is give you a window into a part of your biology that routine labs ignore entirely, and let you watch whether interventions like dietary change, weight loss, or gut-focused therapies are shifting your bile acid pool in a healthier direction over time.
Bile acids are molecules your liver makes from cholesterol to help you digest fats. HCA is a hydrophilic (water-loving) bile acid, which makes it gentler on tissues than the more aggressive bile acids your liver also produces. In humans, it is a minor part of the total bile acid pool. It can be made directly by your liver from chenodeoxycholic acid through an enzyme in the cytochrome P450 family, or generated by your gut bacteria from other bile acids.
Because HCA is hydrophilic, it appears to act as a counterweight to the more toxic, hydrophobic bile acids that build up in cholestatic liver disease. When the liver converts chenodeoxycholic acid into HCA by adding a hydroxyl group at the 6-alpha position, the resulting bile acid is less toxic and more easily packaged for excretion in urine. This is one reason researchers describe HCA as part of a protective bile acid pathway, not just a passive byproduct.
The strongest evidence for HCA as a meaningful marker comes from metabolic disease. In a study of 1,575 adults, serum HCA species were lower in people with obesity, prediabetes, and type 2 diabetes. Levels rose after gastric bypass surgery, and baseline HCA predicted who would go into diabetes remission and who would develop new metabolic problems 5 to 10 years later.
In a separate study of 205 people with impaired fasting glucose, total HCA in the blood and the ratio of HCA to chenodeoxycholic acid moved in the opposite direction of three core metabolic markers: BMI (body mass index), insulin resistance, and HbA1c (a measure of average blood sugar over about three months). Lower HCA tracked with worse metabolic numbers. Most of this evidence comes from studies measuring HCA in blood rather than in stool, so applying it to a fecal HCA result requires interpretation rather than direct translation.
In children with Crohn's disease, a treatment called exclusive enteral nutrition (a liquid-only diet that gives the gut a break from solid food) raises fecal HCA, and the children with the highest HCA levels show the biggest reductions in disease severity. In laboratory experiments, HCA suppresses production of TNF-alpha (a protein that drives inflammation) by immune cells called CD4+ T cells. Animal research found that giving HCA reduced colitis severity, though that finding has not been confirmed in humans.
What this means for you: if you are tracking gut inflammation, a low fecal HCA result alongside other markers like calprotectin (an inflammation protein in stool) suggests your bile acid pool may be skewed in a way that fails to dampen immune activity in the gut.
In cholestatic liver diseases like PBC (primary biliary cholangitis) and PSC (primary sclerosing cholangitis), the liver struggles to clear toxic bile acids. In a study of 55 patients with these conditions, adding fenofibrate to standard therapy raised a urinary form of HCA called HCA-6-glucuronide and improved liver lab values. The pattern fits a model where HCA is part of how the body offloads toxic bile acids safely. This study measured urinary HCA-glucuronide rather than fecal HCA, so it is supportive rather than direct evidence for a stool-based test.
In a study of 230 children, those with NAFLD (nonalcoholic fatty liver disease, fat buildup in the liver not driven by alcohol) showed altered patterns of taurine-conjugated HCA after a glucose drink, and these patterns correlated with glucose, insulin, and C-peptide responses. The bile acid pattern helped distinguish children with NAFLD from those who were obese without fatty liver, and from healthy children.
In an exploratory study of adults with MAFLD (metabolic dysfunction-associated fatty liver disease), those who also had HFpEF (a form of heart failure where the heart muscle is stiff but pumps a normal fraction) had lower serum HCA than those without the heart condition. This is a small study and the relationship may run in either direction, but it supports the idea that HCA is part of a metabolic-cardiac axis worth watching.
In a small case-control study comparing 32 people with osteoporosis to 32 controls, several HCA species emerged as candidate biomarkers. Individual bile acids in the panel reached AUC (area under the curve, a measure of how well a test separates two groups) values of 0.718 to 0.928, and the combined panel achieved 100% accuracy in distinguishing osteoporosis cases from controls in this small sample. The connection between bile acids and bone is mechanistically plausible but early-stage, and these findings have not been replicated in larger populations.
There are no published clinical reference ranges for fecal HCA from major guideline bodies. The numbers reported in research come from specific cohorts using specialized lab techniques (typically liquid chromatography paired with mass spectrometry, a method that separates and weighs molecules), and they are not standardized across labs. What follows is research-derived orientation, not a clinical target.
| Setting | What Was Observed | Source |
|---|---|---|
| Adults with type 2 diabetes vs healthy controls | Lower serum HCA species in people with diabetes | Zheng et al. 2021 |
| Children with Crohn's disease responding to nutrition therapy | Higher fecal HCA after treatment correlated with better symptom control | Xiao et al. 2022 |
| Adults with MAFLD plus heart failure with preserved ejection fraction | Lower serum HCA species than MAFLD alone | Zhou et al. 2024 |
Because HCA testing varies significantly between labs and specimen types, compare your results within the same lab over time rather than treating any single number as a hard threshold. The directional message is consistent across studies: higher HCA tends to align with better metabolic and inflammatory profiles, and lower HCA with worse ones.
A single HCA reading is far less useful than a series. Bile acid levels can shift with diet, gut microbiome composition, recent meals, and acute stress. Get a baseline now, retest in 3 to 6 months if you are making changes (dietary shifts, new medications, weight loss interventions, gut-focused treatments), and at least annually after that to watch the trajectory.
What you are looking for is direction of travel. If your HCA is rising while your HbA1c is falling, your bile acid biology is shifting in the same direction as your metabolic health, which is reassuring. If your HCA is dropping while your weight or inflammation markers are climbing, that is a signal to look more closely at your gut, your diet, and your overall metabolic picture.
If your HCA is low and you have other warning signs (rising HbA1c, growing waistline, elevated triglycerides, fatty liver on imaging), treat your HCA as one piece of a metabolic dysfunction picture rather than an isolated finding. The next step is to address the underlying drivers: pair the HCA result with a full metabolic workup including fasting insulin, HbA1c, lipids, and liver enzymes.
If your HCA is low alongside gut symptoms (chronic diarrhea, abdominal pain, bloating), pair it with stool calprotectin and pancreatic elastase to assess inflammation and digestive function. A gastroenterologist can interpret the combined picture. If you are using HCA to monitor response to a specific intervention (a dietary protocol, a bariatric procedure, a bile acid modulating medication), the most informative pattern is whether HCA moves in the expected direction at the expected timeframe rather than whether it crosses any specific threshold.
Evidence-backed interventions that affect your Hyocholic Acid level
Hyocholic Acid is best interpreted alongside these tests.